Open AccessPlasma level of metastasis‐associated lung adenocarcinoma transcript 1 is associated with liver damage and predicts development of hepatocellular carcinoma
Author(s) -
Konishi Hirotaka,
Ichikawa Daisuke,
Yamamoto Yusuke,
Arita Tomohiro,
Shoda Katsutoshi,
Hiramoto Hidekazu,
Hamada Junichi,
Itoh Hiroshi,
Fujita Yuji,
Komatsu Shuhei,
Shiozaki Atsushi,
Ikoma Hisashi,
Ochiai Toshiya,
Otsuji Eigo
Publication year - 2016
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.12854
Subject(s) - hepatocellular carcinoma , medicine , cirrhosis , adenocarcinoma , metastasis , colorectal cancer , liver disease , cancer , gastroenterology , pathology , carcinoma , oncology
Recent studies have shown that metastasis‐associated lung adenocarcinoma transcript 1 ( MALAT 1) was overexpressed in many human solid cancers, however, its roles in plasma of hepatocellular carcinoma ( HCC ) patients were unclear. The aim of this study was to investigate the significance of plasma MALAT 1 levels in HCC patients. Plasma samples were collected from pre‐operative HCC , hepatic disease patients, and healthy controls, and tissue samples from HCC patients and colorectal cancer patients with liver metastasis. Plasma and tissue MALAT 1 levels were measured. Plasma MALAT 1 levels were progressively and significantly higher in HCC patients than hepatic disease patients, and higher in hepatic disease patients than healthy controls. The expression of MALAT 1 in HCC tissue was slightly higher than that in paired non‐cancerous liver tissue, but not significant. The expression of MALAT 1 in the non‐cancerous liver tissue of 20 HCC patients was significantly higher than that in normal liver tissue of 13 colorectal cancer patients. In contrast, plasma MALAT 1 levels were significantly low in HCC patients with hepatitis B infection, and significantly high in patients with liver damage B or liver cirrhosis. In a receiver–operator curve analysis of HCC and hepatic disease patients, the cut‐off value of plasma MALAT 1 was 1.60 and the area under the curve was 0.66. Plasma MALAT 1 levels were not correlated with α‐fetoprotein or protein induced by vitamin K absence II , whereas sensitivity and specificity for the detection of HCC with the combination of MALAT 1, α‐fetoprotein, and protein induced by vitamin K absence II were 88.6% and 75%, respectively. In conclusion, the plasma MALAT 1 level is associated with liver damage, and has clinical utility for predicting development of HCC .